Michael Wechsler, ERS 2020 – Dupilumab in the LIBERTY ASTHMA TRAVERSE Trial
We discuss with Michael Wechsler (National Jewish Health, Denver, CO, USA) the clinical evidence supporting the use of dupilumab in patients with asthma and specifically the major findings from the long-term safety evaluation of dupilumab in the LIBERTY ASTHMA TRAVERSE trial (NCT02134028).
1. What are the major unmet needs in the biologic treatment of moderate to severe asthma? (0:17)
2. Could you tell us a little about dupilumab, its mechanism of action and its advantages compared to other biologic therapies? (1:30)
3. What clinical evidence supports the efficacy and safety of dupilumab? (3:20)
4. Could you give us a brief overview of the LIBERTY ASTHMA TRAVERSE study and its major findings? (5:05)
5. Which patients are most likely to benefit from dupilumab therapy? (6:50)
Disclosures: Michael Wechsler has acted as a consultant for Sanofi Aventis, Regeneron, Amgen, AstraZeneca, Teva, GSK, Novartis, Genentech, Equillium, Cohero and Boehringer Ingelheim.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In Asthma
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
Ronald Strauss, AAAAI 2023: Hot topics to explore in the field of respiratory medicine
touchRESPIRATORY were delighted to speak with a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), about the areas in the field of respiratory medicine that he is most looking forward to exploring in 2023. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!